Denmark’s Novo Nordisk (CPH: NOVO-B), through its Pharmatech division, announced a partnership this week with U.S. raw materials supplier Actylis. The agreement facilitates the distribution of Novo’s benzalkonium chloride (BKC) in Germany, Ireland, Spain, Portugal, and the UK, expanding upon an existing deal for North American markets.
Benzalkonium chloride is a crucial component in the pharmaceutical and medical device sectors, widely utilized as both an active pharmaceutical ingredient (API) and an excipient.- Flcube.com
